Private Comparative Effectiveness Arbiter Is In Industry’s Interest – Attorney
This article was originally published in The Gray Sheet
Executive Summary
Industry should develop a third-party comparative effectiveness review organization to preclude Congress from creating a similar body, Sidley Austin Brown & Wood partner Patrick Morrisey said Dec. 5
You may also be interested in...
FDA’s Gottlieb: Any FDA/CMS Collaboration Efforts Should Occur Postmarket
FDA and CMS should streamline their internal review processes before pursuing collaborative efforts to avoid an overly burdensome review process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
FDA’s Gottlieb: Any FDA/CMS Collaboration Efforts Should Occur Postmarket
FDA and CMS should streamline their internal review processes before pursuing collaborative efforts to avoid an overly burdensome review process, according to FDA Deputy Commissioner for Medical & Scientific Affairs Scott Gottlieb, MD
Reimbursement News In Brief
Genzyme keeps separate HCPCS code: Genzyme's Synvisc hyaluronic acid-based product for treating osteoarthritic knee joints will continue to be paid at a higher rate than competing products in 2006, the firm announced Nov. 8. The decision maintains the 2005 rates and reverses CMS' proposal to place all viscosupplement products in the same J-code. Synvisc competes with Johnson & Johnson/Ortho Biotech'sOrthovisc, Sanofi-Aventis' Hyalgan and Smith & Nephew's Supartz (1"The Gray Sheet" June 20, 2005, p. 3). Orthovisc will continue to be paid using miscellaneous codes, according to the firm...